Announcements and Financial Documents - Brain+ Better brain better life

COMPANY ANNOUNCEMENTS

Warrants of Series TO1 expected subscribed to approximately 82% of the offered amount and Brain+ A/S to receive approximately DKK 6,4m before issuing costs

Company Announcement Copenhagen, Denmark October 31, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+” or the “Company”) today announces the preliminary outcome of the exercise of warrants of series TO1 (the “Warrants”), which were issued in connection with the Company’s IPO on Nasdaq First North Growth Market, Denmark in October 2021. In total, 3.904.606 Warrants have been exercised to subscribe for 3.904.606 new shares at the exercise price of DKK 1.638 per share. Brain+ is expected to receive approximately DKK 6,4m before issuing costs, through the exercise of the Warrants.

Brain+ CEO and Board members exercise IPO warrants to subscribe for new shares in Brain+ A/S for DKK 0.5m

Company Announcement Copenhagen, Denmark, October 17, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) The information communicated in this announcement is “inside information” for the purposes of article 19 of the Market Abuse Regulation 596/2014 On October 17[th] 2022, Kim Baden-Kristensen, CEO & Co-founder of Brain+ A/S (“Brain+) and members of the board of Brain+, Lars Terney, Vice Chairman, and Hanne Leth Hillman, Chair of the Audit Committee (collectively “the Investors”), chose to exercise all of their warrants of series TO 1 (BRAINP TO, ISIN: DK0061670551), to subscribe for newly issued shares in Brain+ A/S.

Brain+ announces details on the exercise of IPO warrants to subscribe for new shares, including the exercise price for the warrants

Company Announcement Copenhagen, Denmark, October 14, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) In connection with Brain+’s IPO in October 2021, the company issued 4.8m publicly traded warrants, which can be exercised to subscribe for new shares in Brain+ A/S between October 17[th] and October 31[st] 2022, at an exercise price of DKK 1,638 per share. Please find relevant information and terms on the Brain+ website (www.brain-plus.com).

The pricing period for Brain+’s warrants of series TO 1 is underway

Company Announcement Copenhagen, Denmark October 7, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) The pricing period for Brain+’s warrants of series TO 1 (BRAINP TO, ISIN: DK0061670551) is underway. These warrants will from October 17[th] to October 31[st] be exercisable into newly issued Brain+ A/S shares at a 30% discount to the volume-weighted average price of shares traded from October 3[rd] to October 14[th], 2022.

Interim Report for the Period 1. January 2022 – 30. June 2022

Company Announcement Thursday, September 29, 2022, 10:00 CET Brain+ A/S (“Brain+”) [BRAINP], today publishes the Interim Report for the Period 1. January 2022 – 30. June 2022

Brain+ A/S appoints Anders Härfstrand as new Chairman of the Board

Company Announcement Monday, September 5, 2022, 10:00 CET The information communicated in this announcement is “inside information” for the purposes of article 7 of the Market Abuse Regulation 596/2014 Brain + A/S (“Brain+”) today announced Anders Härfstrand, who was elected to the board of directors at the company’s Extraordinary General Meeting on September 2, 2022, has been appointed new Chairman of the Board. Anders Härfstrand has extensive international life science industry and leadership experience, and succeeds Lars Terney, who continues on the board as Vice Chairman after having served as Chairman for the past year.[ ]

Brain+ announces results of Extraordinary General Meeting of Shareholders

Copenhagen, Denmark – 2 September 2022 – Brain+ A/S (“Brain+”) [BRAINP], today announced the results of the Extraordinary General Meeting of Shareholders of Brain+ (“EGM”) which was held on 2 September 2022.

Brain+ A/S intends to add three international life science profiles as new board members in a strategic move ahead of its near-term commercial launch

Monday, August 8, 2022, 8:30 CET The Board of Directors of Brain+ A/S (“Brain+”) hereby notifies of its intention to convene an Extraordinary General Meeting (“EGM”) on Friday, September 2, 2022. The purpose of the EGM is the election of three new board members, nominated as candidates by the Board of Directors: Anders Härfstrand, Chairman of Diurnal Group, Johan Luthman, EVP & Head of R&D at Lundbeck, and Betül Susamis Unaran, Member of the Board of Directors of Ypsomed. The candidates represent a valuable span of international competencies of high relevance for Brain+’s near-term move into commercialization and subsequent business expansion.

Notice of Extraordinary General Meeting of Brain+ A/S

The shareholders of Brain+ A/S are hereby invited to attend an Extraordinary General Meeting on Friday 2[nd] September 2022 at 09:00 (CEST). The Extraordinary General Meeting will take place at Købmagergade 53, 3. 1150 Copenhagen as a physical event.

Minutes of the Annual General Meeting 2022 in Brain+ A/S

On Wednesday 18th of May at 14:00 CET Brain+ A/S held its Annual General Meeting at Hauser Pl. 20, 5., 1127 København.

Notice of Annual General Meeting of Brain+ A/S and Change to the Board of Directors

Invitation to Annual General Meeting The shareholders of Brain+ A/S are hereby invited to attend the Annual General Meeting scheduled for 18th May 2022, 14:00. The general meeting will be take place at Hauser Pl. 20, 5., 1127 København as a physical event.

Annual Report 2021 for Brain+ A/S

Brain+ annual report for 2021 is now available on the Company´s website

Positive results from the first of four clinical studies to evaluate Brain+’ Starry Night cognitive test for early detection of Alzheimer’s Disease

BRAIN+ A/S (BRAINP) Company Announcement No. 2-2022 Thursday, February 3., 2022, 09:00 CET The information communicated in this announcement is “inside information” for the purposes of article 7 of the Market Abuse Regulation 596/2014

Brain+ A/S (BRAINP) appoints Chief Financial Officer

BRAIN+ A/S (BRAINP) Company Announcement No. [1-2022] [Thursday January 27, 2022, 17:00 CET]

Brain+ lands first large-pharma partnership deal to enter the German market for dementia products

BRAIN+ A/S (BRAINP) Company Announcement No. 4-2021 Wednesday, December 15, 2021, 8:20 CET The information communicated in this announcement is “inside information” for the purposes of article 7 of the Market Abuse Regulation 596/2014 Brain+ has signed a partnership agreement with RoX Health (https://roxhealth.com/), a subsidiary of the global pharma company Roche in Germany, to bring its first dementia products to the German market.

Board member announces intention to leave board

BRAIN+ A/S (BRAINP) Company Announcement No. 3-2021 Tuesday November 16, 2021, 22:05 CET

Brain+ IPO 169% subscribed by 1,288 investors

The total subscription in the IPO was DKK 25.4 million from a total of 1,288 subscribers, translating into a subscription percentage of 169% counting all shares offered in the offering.

Danish Digital Medicine Company Brain+ Goes Public

THURSDAY, SEP 16, 2021 Brain+ A/S is offering Units and has applied for admission to trading on Nasdaq First North Growth Market Denmark.

INVESTOR NEWS

Brain+ adds new clinical and development competencies to accelerate and support market access of its digital dementia product portfolio

Copenhagen, Denmark, October 27, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) · Rising star clinical dementia researcher to join the company in a new position as Clinical Director · Recently, development was also strengthened with a Quality Manager and a Clinical Research Associate · The new hires represent a significant competence upgrade and expansion of the clinical team for a more efficient product development and commercialization

Investor Update: Exercise via Nordnet of TO1 warrants possible until October 27[th] 2022

Copenhagen, Denmark October 24, 2022 – Brain+ A/S (Nasdaq First North: BRAINP)

Brain+ further advances its first digital dementia product, Cognitive Stimulation Therapy (CST)-Therapist Companion

Copenhagen, Denmark, October 24, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) · Commercial launch in Denmark will be November 1, 2022 · Adaptation of a UK product version for the United Kingdom starts November 1[st] in collaboration with a key UK CST researcher, the exact launch timing will be announced later.

Brain+ begins early activity and brand building in the US

Copenhagen, Denmark, October 19, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) · The United States (US) is a key future market for Brain+, and early brand building and exploration is now ongoing · Brain+ has been selected and featured as a 2022 TMC-Denmark BioBridge Partner in the new Texas Medical Center (TMC) new 2022 Biobridge e-book. TMC is the largest medical city in the world · 7+ million people ages 65 or older had in the US dementia in 2020 · US reimbursement/price levels for Digital Therapeutics (Dtx) at $1000 and beyond · The US market potential for DTx for dementia is estimated to be more than $2 billion

Brain+ meets the first milestone in its pharma partnership with Rox Health (Roche Germany) on its digital Cognitive Stimulation Therapy products

Copenhagen, Denmark, October 12, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) · Rox Health has approved the German version of Brain+’s first digital dementia product, CST-Therapist Companion, for commercial launch · Meeting this milestone unlocks access for Brain+ to additional expert resources in the Rox Health/Roche organization and triggers a minor milestone payment · The next milestones will be product launch in Germany, targeted for Q2 2023, and getting the first German customers · The German market for digital dementia therapeutics is estimated at €400 million.

Swedish-based Analyst Group releases first commissioned equity research of Brain+ A/S and base case values the company at DKK 4.1 per share

Copenhagen, Denmark, October 11, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) Swedish-based research group, Analyst Group, which is specialized in life science and technology companies, has today published a 24-page commissioned equity research paper on Brain+, a pioneer in the development of digital therapeutics for Alzheimer’s disease and dementia. They find Brain+ to be “in a strong position to grow towards a market leadership position within Digital Therapeutics for dementia, based on a unique and differentiated product offering [...] combined with a strong clinical pipeline”.

Brain+ informs of new IR initiatives, including initiation of commissioned research, and invites to its first live Investor Update

Copenhagen, Denmark October 11, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+”) has upped its investor relations strategy to include a number of new initiatives with the intention to further increase transparency towards investors on the company’s business activities and progress. In addition, the company has made an agreement with AG Equity Research AB (“Analyst Group”) to undertake commissioned equity research.

World Alzheimer's Report 2022 highlights Cognitive Stimulation Therapy

Copenhagen, Denmark, October 7, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) The recently published World Alzheimer Report 2022 (21. September 2022) highlights Cognitive Stimulation Therapy (CST), the therapy form that Brain+ is digitalizing with global experts, as a cost-effective evidence-based therapy for people with mild-to-moderate dementia that should be researched and implemented globally.

Summary from H1 2022 report: Brain+ (BRAINP) on track for accelerated first dementia product launches in Denmark and Germany in 2022 and 2023

Copenhagen, Denmark, September 29, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) “We are dedicated to helping people with dementia and Alzheimer’s disease as well as their families and caregivers, through the use of our suite of unique and clinically validated Digital Therapeutics. The net financial result in H1 2022 reflects the addition of organizational competencies as well as a higher activity level and was fully in line with expectations. Since the start of the year, our partnership with RoX (part of Roche) has helped identify a faster route to market and fueled accelerated product development of Cognitive Stimulation Therapy – Therapist Companion. Consequently, we have been able to advance commercial launch of the product in Denmark to Q4 this year and in Germany to Q2 2023”, said Kim Baden-Kristensen, CEO of Brain+

Brain+ partners with German medical distributor – and advances launch of its first CST dementia product in Germany to Q2 2023

Copenhagen, Denmark, September 28, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) · Through Coopmed, Brain+ will be represented by experienced and local medical sales managers in Germany and begin to build the customer pipeline in preparation for the commercial launch of its first CST dementia product, CST-Therapist Companion · In partnership with Rox Health (part of Roche Germany), Brain+ has successfully completed the regulatory and commercial preparation of CST-Therapist Companion for the German market and now advances its launch plan with six months to Q2 2023 · The German market for the Brain+ digital CST dementia products is estimated at € 400 million. There are 2,275 nursing homes specialized in dementia in Germany.

Brain+’ new digital product for dementia, “CST–Therapist Companion” is ready for commercial launch in Denmark in Q4 2022 – one year ahead of plan

BRAIN+ A/S (BRAINP) · The Brain+ “CST-Therapist Companion” is a new digital product to deliver Cognitive Stimulation Therapy (CST), a globally recognized evidence-based non-pharmaceutical dementia therapy · The Danish market for the Brain+ digital CST products, of which CST-Therapist Companion is the first, is estimated at € 30 million · CST is used in 35 countries today, and Brain+ is the first to offer a digital version of the therapy

Brain+ is experiencing growing interest from big pharma in its Digital Therapeutics solutions for dementia

Brain+ is a first mover in the field of Digital Therapeutics (DTx) solutions to treat Alzheimer’s Disease (AD) and other types of dementia and help relieve the growing burden of these conditions on patients, relatives, and societies. According to the World Health Organization, currently, more than 55 million people live with dementia worldwide, and there are nearly 10 million new cases every year.

Common Nordic digital health evaluation framework launched

Digital Therapeutics (DTx) is a growing trend and is increasingly a recognized market providing an important supplement to the established trillion USD pharmaceutical market (traditional medicine). The DTx trend is evolving fast. In June 2022 the Nordic Digital Health and Evaluation Criteria (NordDEC) program has been created. The NordDEC is a world-first program to unify digital health standards across multiple countries, delivering safe digital health across Sweden, Denmark, Norway, Finland, and Iceland.

Germany opens the DiPA reimbursement pathway to support the adoption of digital health applications, underpinning the value of the #1 target market for Brain+’ first commercial dementia product, CST

· A significant event for Brain+ as DiPA can provide reimbursement coverage for the first Cognitive Stimulation Therapy (CST) product, expected to be launched in Germany in 2023 · The CST product fits well with the requirements of the DiPA reimbursement pathway. The goal of the DIPA is to reimburse products that stabilize patients' health with special training programs or facilitates communication with family members and nursing care professionals, and this is the same purpose as the product. · The DIPA pathway can thus enable access to the Brain+ CST products for the 1 million Germans living with mild-to-moderate dementia, which is the target segment for the CST products.

1m SEK FORTE grant project to map state of the art digital interventions for dementia begins, helping Brain+ to strengthen patient and caregiver compliance for product development

· PURPOSE: The FORTE project will perform a scoping review of digital interventions for dementia and mild cognitive impairment and engage with live user panels to map out the state-of-the-art in the field. Brain+ focus is to strengthen knowledge on caregiver compliance for product development. Caregiver compliance impacts patient health outcomes and makes the Brain+ digital Cognitive Stimulation Therapy (CST) products scalable. · Brain+ PRODUCT RELEVANCE: The Brain+ dementia treatment product, Cognitive Stimulation Therapy (CST) – Home Extension, which is the 2[nd] product in the CST product line. The product relies on a caregiver to interact with the person with dementia when the CST therapy is done at home. This is not an issue when CST is done in a clinic, which is the case for the 1[st] product CST – Therapist Companion, where the therapy is led by a trained CST professional.

Summary from Annual Report 2021: Brain+ (BRAINP) is ahead of its IPO plan

“We are dedicated to helping people with dementia and Alzheimer’s disease – their families and their caregivers – through the use of our unique Digital Therapeutic software solutions that are being developed and validated through rigorous scientific and clinical trials. 2021 brought us closer to this core objective and we are now in a strong position to launch our first dementia product in 2023, 2 years ahead of plan. This will be a highly important commercial first step towards leadership in an emerging US billion-dollar market”, said Kim Baden-Kristensen, CEO of Brain+.

Brain+ CTO unfolds the Company’s Technology Platform Strategy

Paula Petcu joined Brain+ as new Chief Technology Officer after the company’s IPO in 2021, and is now driving forth the company’s product development work and technology platform initiatives. She came from Lundbeck A/S, a pioneering pharma company within central nervous system (CNS) disorders, where she built up the digital health organization. In this article, she explains the Brain+ platform strategy and technology stack. Summary highlights · Platform strategy: We are building a technology platform that is both modular, scalable, configurable, and regulatory compliant, while also allowing for high-quality data collection and easy integration with other apps and platforms. · Technology Stack: Our therapeutic software solutions are developed for both web and mobile applications using Flutter, which is a worldwide recognized framework for building multi-platform applications from a single codebase. We build on a German-based cloud infrastructure to ensure compliance with German and European data privacy requirements. And we use a microservices architecture for the flexibility and modularity of our products.

Brain+ selected as ‘digital showcase for Denmark’ by Digital Hub Denmark

Brain+ has been selected as showcase in the HealthTech category, among other top cutting-edge start-ups from Denmark, who are leading the digital transformation of society. The selection of Brain+ is motivated by the company’s achievements and commitment to make effective dementia and Alzheimer’s treatments available to everyone, as digital medicine.

The Danish Foreign Ministry to promote Brain+ into elderly care homes in Germany – Europe’s largest Alzheimer’s market

Brain+ has been identified by the Danish Foreign Ministry as a high potential Danish medtech company relevant for the German market. Therefore, Brain+ has been invited into the Danish-German Care Alliance (Dänisch-Deutsche Pflegeallianz), which aims to put Danish medical technologies directly into the hands of relevant large German customers. In practice, this means that Brain+ will get the opportunity to engage in a structured series of workshops with six large care home chains during 2022 with the aim of establishing local pilots and lead customers for the product launch in 2023.

Brain+ and Biogen preparing for commercialization in Germany, the #1 EU market for digital therapeutics

Brain+ has been selected to Biogen’s and EIT Health’s exclusive Neurotech-prize program. This will give additional momentum to the preparations for launch of Brain+’s first dementia product on the German market in 2023. The German market is a global ‘reference’ market for Digital Therapeutics (DTx) products and succeeding here creates a strong base for global expansion.

Publication of results from an earlier study that showed cognitive improvements in people with Brain Injury after training with Brain+ Recover Computerized Cognitive Training product

BRAIN+ A/S Investor update · Critical, early validation of Brain+ Computerized Cognitive Training technology as effective on specific cognitive outcomes relevant for patients with dementia · Cognitive problems are primary symptoms in pre-stages of dementia and often caused by Alzheimer’s disease · Insights from this study have been built into both the design of Brain+’ new dementia product, Cognitive Stimulation Therapy, and the next generation of cognitive training Brain+ is devoloping to target pre-stages of dementia in Alzheimer’s patients

Known data from a pilot study that tested an early version the Brain+ Computerized Cognitive Training technology in Parkinson’s Disease has been published

BRAIN+ A/S Investor update · Feasibility of use by Parkinson’s patients was shown · Valuable information gained about patient compliance that is relevant for the products Brain+ is developing for Alzheimer’s and dementia · Insights from the study have been built into the Computerized Cognitive Training technology, which is currently being tested in people at risk of dementia, and from which results are expected later this year